P893: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS PHYSICIAN’S CHOICE THERAPY IN TRIPLE-CLASS EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHED COHORT ANALYSIS

• Albert Oriol,
• Keqin Qi,
• Anil Londhe,
• Sandhya Nair,
• Xiwu Lin,
• Lixia Pei,
• Eric Ammann,
• Christoph Heuck,
• Thomas Renaud,
• Colleen Kane,
• Trilok Parekh,
• Steve Peterson

Affiliations

Albert Oriol

1 Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain

Keqin Qi

2 Janssen Research & Development, Titusville, United States

Anil Londhe

2 Janssen Research & Development, Titusville, United States

Sandhya Nair

3 Janssen Pharmaceutica NV, Beerse, Belgium

Xiwu Lin

4 Janssen Global Services, Horsham, United States

Lixia Pei

5 Janssen Research & Development, Raritan, United States

Eric Ammann

6 Janssen Global Services, Raritan, United States

Christoph Heuck

7 Janssen Research & Development, Spring House, United States

Thomas Renaud

5 Janssen Research & Development, Raritan, United States

Colleen Kane

7 Janssen Research & Development, Spring House, United States

Trilok Parekh

8 Janssen Research & Development, Bridgewater, United States

Steve Peterson

9 Janssen Research & Development, Horsham, United States